Telik Inc. (TELK) Friday reported fourth-quarter net loss of $.177 million or $0.66 per share, narrower than $2.50 million or $1.38 per share reported last year.
Loss for the three-month period narrowed due to lower expenses. Research and development for the period dropped to $736 thousand from $1.10 million last year. General and administrative costs declined to $1.03 million from $1.40 million last year.
Palo Alto, California-based Telik is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.